Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10387MR)

This product GTTS-WQ10387MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Autoimmune diseases, Rheumatoid arthritis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10387MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14258MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RG-7116
GTTS-WQ7007MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA F-627
GTTS-WQ12305MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MT203
GTTS-WQ13333MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ11397MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ3550MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAX069
GTTS-WQ979MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ5908MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CIM 331
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW